Target Hormone Levels for Postmenopausal Women on HRT
Hormone replacement therapy should not be monitored by measuring serum hormone levels; instead, treatment should be guided by symptom relief using the lowest effective dose, with dose titration based on clinical response rather than laboratory values. 1, 2
Estradiol
The Endocrine Society explicitly states that clinicians usually do not measure estradiol levels to monitor therapy except when symptoms do not improve with escalating doses, particularly after changing from oral to transdermal administration 1. This represents the current standard of care - dose adjustment is symptom-driven, not lab-driven.
However, when levels are measured, the research provides some context:
- Minimum effective threshold: Estradiol levels as low as <15 pg/ml (55 pmol/L) are sufficient to suppress gonadotropins and relieve vasomotor symptoms 3
- Bone protection threshold: At least 15-25 pg/ml (55-92 pmol/L) is needed to prevent bone loss, with one study suggesting 60 pg/ml (220 pmol/L) as optimal 3, 4
- Lipid benefits: Levels >25 pg/ml (92 pmol/L) are required to reduce total cholesterol and LDL 3
- Real-world variation: A 2025 study found median estradiol levels of 355 pmol/L (~97 pg/ml) in women using transdermal estradiol, with a reference interval of 54-2,050 pmol/L (15-560 pg/ml), demonstrating massive interindividual variation 5
Critical Pitfall
One in four women using the highest licensed transdermal estradiol dose had subtherapeutic levels (<200 pmol/L or ~55 pg/ml) 5. This underscores why symptom-based dosing is essential - laboratory values alone don't predict clinical response.
Progesterone
Progesterone levels are not monitored during HRT. The sole purpose of progestogen therapy is endometrial protection in women with a uterus 1, 2. Standard dosing regimens include:
- Micronized progesterone: 100 mg daily (continuous) or 200 mg for 10-12 days/month (cyclic)
- Medroxyprogesterone acetate: 2.5 mg daily (continuous) or 5 mg for 10-12 days/month (cyclic)
No target serum progesterone level exists because the goal is tissue effect (preventing endometrial hyperplasia), not achieving specific blood concentrations.
Testosterone
Testosterone supplementation is not part of standard HRT, and routine testosterone monitoring is not recommended 1, 2.
Important considerations:
- HRT decreases endogenous testosterone: Estrogen therapy reduces testosterone by approximately 42% and DHEA-sulfate by 23% through decreased LH-driven ovarian production and increased SHBG (which rises 160% with estrogen) 6
- Population reference: Among postmenopausal U.S. women not on HRT, mean total testosterone is 25.2 ng/dL, with 80% having levels <30 ng/dL 7
- No established deficiency threshold: There is no universally accepted diagnostic cutoff for testosterone deficiency in women 7, 8
If testosterone supplementation is considered for persistent symptoms despite adequate estrogen therapy, this represents off-guideline use requiring specialist consultation.
Practical Algorithm
- Start with standard doses (e.g., transdermal estradiol 50 μg/day or oral estradiol 1 mg/day) 1
- Titrate based on symptom relief at 4-12 week intervals
- Use the lowest effective dose that controls symptoms
- Only measure estradiol if:
- Symptoms persist despite dose escalation
- Route of administration changes (oral to transdermal)
- Suspicion of poor absorption
- Never measure progesterone or testosterone for routine HRT monitoring
- Never use FSH levels to guide estrogen dosing - they remain elevated despite adequate tissue effects 2
Key Caveat for Younger Women
Women with premature ovarian insufficiency or surgical menopause may require higher starting doses (e.g., transdermal estradiol 100 μg) since they're accustomed to higher premenopausal estradiol levels 1. Even in these cases, dosing remains symptom-guided rather than lab-guided.